Alan Simon Pickard

List of Publications by Citations

Source: https://exaly.com/author-pdf/308865/alan-simon-pickard-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6,800 80 153 39 h-index g-index citations papers 165 8,154 5.86 3.1 avg, IF L-index ext. citations ext. papers

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 153 | Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. <i>Value in Health</i> , 2012 , 15, 708-15 | 3.3 | 946 |
| 152 | Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Quality of Life Research</i> , 2013 , 22, 1717-27 | 3.7 | 786 |
| 151 | Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2007 , 5, 70 | 3 | 512 |
| 150 | Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. <i>Medical Care</i> , 2000 , 38, 115-21 | 3.1 | 210 |
| 149 | Health utilities using the EQ-5D in studies of cancer. <i>Pharmacoeconomics</i> , 2007 , 25, 365-84 | 4.4 | 199 |
| 148 | Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. <i>Medical Care</i> , 2007 , 45, 259-63 | 3.1 | 157 |
| 147 | Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. <i>Stroke</i> , 2004 , 35, 607-12 | 6.7 | 150 |
| 146 | Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. <i>Medical Care</i> , 2005 , 43, 493-9 | 3.1 | 150 |
| 145 | Responsiveness of generic health-related quality of life measures in stroke. <i>Quality of Life Research</i> , 2005 , 14, 207-19 | 3.7 | 131 |
| 144 | Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. <i>Annals of Internal Medicine</i> , 2008 , 149, 380-90 | 8 | 118 |
| 143 | Validity of EQ-5D-5L in stroke. <i>Quality of Life Research</i> , 2015 , 24, 845-50 | 3.7 | 116 |
| 142 | Use of a preference-based measure of health (EQ-5D) in COPD and asthma. <i>Respiratory Medicine</i> , 2008 , 102, 519-36 | 4.6 | 112 |
| 141 | Assessment of patient functional status after surgery. <i>Journal of the American College of Surgeons</i> , 2005 , 201, 171-8 | 4.4 | 112 |
| 140 | Visual analog scales for assessing surgical pain. <i>Journal of the American College of Surgeons</i> , 2005 , 201, 245-52 | 4.4 | 106 |
| 139 | Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. <i>International Journal of Clinical Practice</i> , 2012 , 66, 1056-78 | 2.9 | 105 |
| 138 | Disease-specific patient reported outcome tools for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 56-65 | 5.3 | 93 |
| 137 | Replicability of SF-36 summary scores by the SF-12 in stroke patients. <i>Stroke</i> , 1999 , 30, 1213-7 | 6.7 | 90 |

| 136 | Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. <i>Pediatric Pulmonology</i> , 2019 , 54, 179-185 | 3.5 | 87 | |
|-----|---|-------------------|----|--|
| 135 | Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 441-8 | 4.7 | 84 | |
| 134 | Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. <i>Quality of Life Research</i> , 2015 , 24, 1555-63 | 3.7 | 83 | |
| 133 | United States Valuation of EQ-5D-5L Health States Using an International Protocol. <i>Value in Health</i> , 2019 , 22, 931-941 | 3.3 | 80 | |
| 132 | Comparison of US panel vendors for online surveys. <i>Journal of Medical Internet Research</i> , 2013 , 15, e260 | 0 ₇ .6 | 77 | |
| 131 | US valuation of health outcomes measured using the PROMIS-29. Value in Health, 2014 , 17, 846-53 | 3.3 | 76 | |
| 130 | Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. <i>Pharmacotherapy</i> , 2008 , 28, 376-92 | 5.8 | 65 | |
| 129 | Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. <i>Health and Quality of Life Outcomes</i> , 2011 , 9, 26 | 3 | 64 | |
| 128 | Exploring factors that influence informal caregiving in medication management for home hospice patients. <i>Journal of Palliative Medicine</i> , 2010 , 13, 1085-90 | 2.2 | 62 | |
| 127 | Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019 , 22, 267-275 | 3.3 | 60 | |
| 126 | Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1209-16 | 4.1 | 60 | |
| 125 | Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general. <i>Value in Health</i> , 2007 , 10, 266-72 | 3.3 | 57 | |
| 124 | Health problems are more common, but less severe when measured using newer EQ-5D versions. Journal of Clinical Epidemiology, 2014 , 67, 93-9 | 5.7 | 52 | |
| 123 | US valuation of the SF-6D. <i>Medical Decision Making</i> , 2013 , 33, 793-803 | 2.5 | 50 | |
| 122 | A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. <i>Journal of the National Cancer Institute Monographs</i> , 2004 , 102-25 | 4.8 | 48 | |
| 121 | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. <i>Health and Quality of Life Outcomes</i> , 2005 , 3, 11 | 3 | 47 | |
| 120 | Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018 , 36, 225-238 | 4.4 | 45 | |
| 119 | Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value in Health 2012 15 916-25 | 3.3 | 43 | |

| 118 | Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. <i>Archives of Internal Medicine</i> , 2009 , 169, 1403-10 | | 42 |
|-----|---|------|----|
| 117 | Body image in patients with systemic lupus erythematosus. <i>International Journal of Behavioral Medicine</i> , 2012 , 19, 157-64 | 2.6 | 40 |
| 116 | Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. <i>Medical Care</i> , 2007 , 45, 812-9 | 3.1 | 40 |
| 115 | Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. <i>BMC Medical Research Methodology</i> , 2014 , 14, 78 | 4.7 | 39 |
| 114 | Bisphosphonate-induced osteonecrosis of the jaw. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 276-84 | 2.9 | 39 |
| 113 | Medication adherence and persistence in the last year of life in COPD patients. <i>Respiratory Medicine</i> , 2009 , 103, 525-34 | 4.6 | 38 |
| 112 | Stakeholder views on pharmacogenomic testing. <i>Pharmacotherapy</i> , 2014 , 34, 151-65 | 5.8 | 36 |
| 111 | An update on evidence of clinical pharmacy servicesRimpact on health-related quality of life. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 1623-34 | 2.9 | 35 |
| 110 | A comparison of depressive symptoms in stroke and primary care: applying Rasch models to evaluate the center for epidemiologic studies-depression scale. <i>Value in Health</i> , 2006 , 9, 59-64 | 3.3 | 35 |
| 109 | Retracted publications in the drug literature. <i>Pharmacotherapy</i> , 2012 , 32, 586-95 | 5.8 | 34 |
| 108 | Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. <i>Medical Care</i> , 2014 , 52, 935-43 | 3.1 | 33 |
| 107 | The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. <i>Health Services Research</i> , 2011 , 46, 1104 | 1-23 | 33 |
| 106 | The impact of pharmacist interventions on health-related quality of life. <i>Annals of Pharmacotherapy</i> , 1999 , 33, 1167-72 | 2.9 | 33 |
| 105 | The societal cost of heroin use disorder in the United States. <i>PLoS ONE</i> , 2017 , 12, e0177323 | 3.7 | 32 |
| 104 | A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). <i>Pharmacoeconomics</i> , 2015 , 33, 867-77 | 4.4 | 31 |
| 103 | Comparison of FACT- and EQ-5D-based utility scores in cancer. <i>Value in Health</i> , 2012 , 15, 305-11 | 3.3 | 31 |
| 102 | Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8877-83 | 2.2 | 31 |
| 101 | A median model for predicting United States population-based EQ-5D health state preferences. <i>Value in Health</i> , 2010 , 13, 278-88 | 3.3 | 30 |

(2009-2007)

| 100 | Pain and depression in caregivers affected their perception of pain in stroke patients. <i>Journal of Clinical Epidemiology</i> , 2007 , 60, 963-70 | 5.7 | 29 |
|-----|--|------------------|----|
| 99 | Comparative effectiveness research: Relevance and applications to pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2009 , 66, 1278-86 | 2.2 | 28 |
| 98 | Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. <i>Clinical Therapeutics</i> , 2016 , 38, 769-7 | 7 ^{3.5} | 25 |
| 97 | Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. <i>Value in Health Regional Issues</i> , 2014 , 4, 19-23 | 1.6 | 24 |
| 96 | Osteoarthritis: a comorbid marker for longer life?. Annals of Epidemiology, 2007, 17, 380-4 | 6.4 | 24 |
| 95 | Evaluation of content on EQ-5D as compared to disease-specific utility measures. <i>Quality of Life Research</i> , 2013 , 22, 853-74 | 3.7 | 23 |
| 94 | Proxy assessment of health-related quality of life in african american and white respondents with prostate cancer: perspective matters. <i>Medical Care</i> , 2009 , 47, 176-83 | 3.1 | 23 |
| 93 | 3L, 5L, What the L? A NICE Conundrum. <i>Pharmacoeconomics</i> , 2018 , 36, 637-640 | 4.4 | 22 |
| 92 | Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. <i>Sleep</i> , 2009 , 32, 817-24 | 1.1 | 22 |
| 91 | Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1301-9 | 4.7 | 21 |
| 90 | A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. <i>Pharmacotherapy</i> , 2003 , 23, 1611-6 | 5.8 | 21 |
| 89 | A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. <i>Value in Health</i> , 2009 , 12, 977-88 | 3.3 | 20 |
| 88 | Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. <i>Pharmacotherapy</i> , 2007 , 27, 852-9 | 5.8 | 20 |
| 87 | Valuation of the EQ-5D-5L in Taiwan. <i>PLoS ONE</i> , 2018 , 13, e0209344 | 3.7 | 20 |
| 86 | Patient preferences in prostate cancer: a clinician guide to understanding health utilities. <i>Clinical Prostate Cancer</i> , 2005 , 4, 15-23 | | 19 |
| 85 | U.K. utility weights for the EORTC QLU-C10D. <i>Health Economics (United Kingdom)</i> , 2019 , 28, 1385-1401 | 2.4 | 18 |
| 84 | The effect of chronic conditions on stated preferences for health. <i>European Journal of Health Economics</i> , 2013 , 14, 697-702 | 3.6 | 18 |
| 83 | Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease. <i>Pharmacotherapy</i> , 2009 , 29, 1039-53 | 5.8 | 18 |

| 82 | Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE). <i>Value in Health</i> , 2014 , 17, 744-8 | 3.3 | 17 | |
|----|--|--------------------|----|--|
| 81 | Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting FAgonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. <i>Annals of Pharmacotherapy</i> , 2017 , 51, 945-953 | 2.9 | 17 | |
| 80 | Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. <i>Journal of Managed Care & Amp; Specialty Pharmacy</i> , 2015 , 21, 114-22 | 1.9 | 17 | |
| 79 | Drugs associated with adverse events in children and adolescents. <i>Pharmacotherapy</i> , 2014 , 34, 918-26 | 5.8 | 17 | |
| 78 | Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020 , 23, 1235-1245 | 3.3 | 17 | |
| 77 | US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. <i>Quality of Life Research</i> , 2021 , 30, 803-816 | 3.7 | 17 | |
| 76 | Using existing data to identify candidate items for a health state classification system in multiple sclerosis. <i>Quality of Life Research</i> , 2014 , 23, 1445-57 | 3.7 | 16 | |
| 75 | Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. <i>European Journal of Health Economics</i> , 2014 , 15, 489-96 | 3.6 | 15 | |
| 74 | Granulocyte colonystimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. <i>Pharmacoeconomics</i> , 2005 , 23, 767-75 | 4.4 | 15 | |
| 73 | Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2017 , 37, 447-455 | 5.8 | 14 | |
| 72 | EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. <i>Journal of Medical Economics</i> , 2017 , 20, 19-27 | 2.4 | 14 | |
| 71 | Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment. <i>Value in Health</i> , 2016 , 19, 1033-1038 | 3.3 | 14 | |
| 70 | Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. <i>Medical Decision Making</i> , 2018 , 38, 968-982 | 2.5 | 14 | |
| 69 | Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. <i>Health Economics (United Kingdom)</i> , 2010 , 19, 101-10 | 2.4 | 13 | |
| 68 | Engaging Patients and Caregivers to Design Transitional Care Management Services at a Minority Serving Institution. <i>Journal of Health Care for the Poor and Underserved</i> , 2016 , 27, 352-365 | 1.4 | 12 | |
| 67 | Transforming Latent Utilities to Health Utilities: East Does Not Meet West. <i>Health Economics</i> (United Kingdom), 2017 , 26, 1524-1533 | 2.4 | 11 | |
| 66 | Do health preferences contradict ordering of EQ-5D labels?. <i>Quality of Life Research</i> , 2015 , 24, 1759-65 | 3.7 | 10 | |
| 65 | EQ-5D-Y for the assessment of health-related quality of life among Taiwanese youth with mild-to-moderate chronic kidney disease. <i>International Journal for Quality in Health Care</i> , 2018 , 30, 298- | 3 0 8 _ | 10 | |

| 64 | Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012 , 10, 110-122.e1 | | 10 |
|----|---|-----|----|
| 63 | A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. <i>Journal of General Internal Medicine</i> , 2021 , 36, 1292-1301 | 4 | 10 |
| 62 | The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319842532 | 1.5 | 9 |
| 61 | Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 888-92 | 6.1 | 9 |
| 60 | Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 4 | 3 | 9 |
| 59 | A Cross Sectional and Longitudinal Study of Pharmacy Student Perceptions of Readiness to Serve Diverse Populations. <i>American Journal of Pharmaceutical Education</i> , 2016 , 80, 62 | 2.5 | 9 |
| 58 | Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. <i>Journal of General Internal Medicine</i> , 2019 , 34, 2029-2037 | 4 | 8 |
| 57 | An instrument to evaluate pharmacistsRpatient counseling on herbal and dietary supplements. <i>American Journal of Pharmaceutical Education</i> , 2010 , 74, 192 | 2.5 | 8 |
| 56 | Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020 , 29, 2651-2660 | 3.7 | 7 |
| 55 | Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1490-6 | 4.7 | 7 |
| 54 | Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8894-905 | 2.2 | 7 |
| 53 | Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2019 , 37, 105-116 | 4.4 | 7 |
| 52 | Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. <i>Quality of Life Research</i> , 2021 , 30, 1433-1444 | 3.7 | 7 |
| 51 | Patient Experience-based Value Sets: Are They Stable?. <i>Medical Care</i> , 2017 , 55, 979-984 | 3.1 | 6 |
| 50 | Exploring the Internal Structure of the EQ-5D Using Non-Preference-Based Methods. <i>Value in Health</i> , 2019 , 22, 527-536 | 3.3 | 6 |
| 49 | Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?. <i>Quality of Life Research</i> , 2018 , 27, 1227-1235 | 3.7 | 6 |
| 48 | A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017. <i>Quality of Life Research</i> , 2019 , 28, 3065-3069 | 3.7 | 6 |
| 47 | Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017 , 18, 967-977 | 3.6 | 6 |

| 46 | disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). <i>Journal of Blood Medicine</i> , 2012 , 3, 131-8 | 2.3 | 6 |
|----|--|---------------|---|
| 45 | Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale. <i>PLoS ONE</i> , 2016 , 11, e0151905 | 3.7 | 6 |
| 44 | Towards supporting scholarship in research by clinical pharmacy faculty. <i>Pharmacy Practice</i> , 2006 , 4, 19 | 1 -4 8 | 6 |
| 43 | Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 265-279 | 1.9 | 6 |
| 42 | Design of the patient navigator to Reduce Readmissions (PArTNER) study: A pragmatic clinical effectiveness trial. <i>Contemporary Clinical Trials Communications</i> , 2019 , 15, 100420 | 1.8 | 5 |
| 41 | Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 937-944 | 5.6 | 5 |
| 40 | Eliciting social preference weights for functional assessment of cancer therapy-lung health states. <i>Pharmacoeconomics</i> , 2006 , 24, 293-4; author reply 294-6 | 4.4 | 5 |
| 39 | Opportunities for disease state management in prostate cancer. <i>Disease Management: DM</i> , 2005 , 8, 235 | 5-44 | 5 |
| 38 | Drug utilization reviews of oral quinolone, cephalosporin, and macrolide use in nonacute care: a systematic review. <i>Clinical Therapeutics</i> , 1999 , 21, 1951-72 | 3.5 | 5 |
| 37 | Feasibility and acceptability of virtual academic detailing on opioid prescribing. <i>International Journal of Medical Informatics</i> , 2021 , 147, 104365 | 5.3 | 5 |
| 36 | Choice Blindness and Health-State Choices among Adolescents and Adults. <i>Medical Decision Making</i> , 2017 , 37, 680-687 | 2.5 | 4 |
| 35 | Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. <i>Journal of Evaluation in Clinical Practice</i> , 2013 , 19, 953-60 | 2.5 | 4 |
| 34 | Impact of oral direct thrombin inhibitors on anticoagulation clinics. <i>Pharmacotherapy</i> , 2004 , 24, 1204-17 | 2 5.8 | 4 |
| 33 | Practice change intentions after academic detailing align with subsequent opioid prescribing. Journal of the American Pharmacists Association: JAPhA, 2020 , 60, 1001-1008 | 1.7 | 4 |
| 32 | The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021 , 24, 862-873 | 3.3 | 4 |
| 31 | Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payers. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 177-180 | 2.1 | 4 |
| 30 | Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. <i>Medical Decision Making</i> , 2019 , 39, 421-436 | 2.5 | 3 |
| 29 | Positive Outcomes of Varicose Vein Surgery: The Patient Perspective. <i>Patient</i> , 2015 , 8, 329-37 | 3.7 | 3 |

(2020-2020)

| 28 | Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. <i>British Journal of General Practice</i> , 2020 , 70, e589-e597 | 1.6 | 3 |
|----|---|-------------------|---|
| 27 | Value of transfusion independence in severe aplastic anemia from patientsRperspectives - a discrete choice experiment. <i>Journal of Patient-Reported Outcomes</i> , 2017 , 2, 13 | 2.6 | 3 |
| 26 | Conceptual development of a measure to assess pharmacistsRknowledge of herbal and dietary supplements. <i>American Journal of Pharmaceutical Education</i> , 2008 , 72, 59 | 2.5 | 3 |
| 25 | Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients: A Matched Cohort Analysis. <i>Medical Care</i> , 2019 , 57, 13-20 | 3.1 | 3 |
| 24 | Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using non-parametric item response theory using an international dataset. <i>Quality of Life Research</i> , 2021 , 1 | 3.7 | 3 |
| 23 | The EQ Health and Wellbeing: Overview of the Development of a Measure of Health and Wellbeing and Key Results <i>Value in Health</i> , 2022 , | 3.3 | 3 |
| 22 | Using linked electronic data to validate algorithms for health outcomes in administrative databases. <i>Journal of Comparative Effectiveness Research</i> , 2015 , 4, 359-66 | 2.1 | 2 |
| 21 | Application of directional statistics to health state valuation: a commentary on Craig and Oppe. <i>Social Science and Medicine</i> , 2010 , 71, 429-430 | 5.1 | 2 |
| 20 | Edmonton Quality Assessment Tool for Drug Utilization Reviews: EQUATDUR-2: the development of a scale to assess the methodological quality of a drug utilization review. <i>Medical Care</i> , 2000 , 38, 948- | 5 8 .1 | 2 |
| 19 | Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021 , 22, 723-733 | 3.6 | 2 |
| 18 | Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021 , 22, 1301-1309 | 3.6 | 2 |
| 17 | General population normative data for the EQ-5D-3L in the five largest European economies. <i>European Journal of Health Economics</i> , 2021 , 22, 1467-1475 | 3.6 | 2 |
| 16 | The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students. <i>American Journal of Pharmaceutical Education</i> , 2019 , 83, 6891 | 2.5 | 2 |
| 15 | Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ Health and Wellbeing <i>Value in Health</i> , 2022 , | 3.3 | 2 |
| 14 | Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. <i>Medical Decision Making</i> , 2020 , 40, 483-497 | 2.5 | 1 |
| 13 | Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 167-175 | 2.1 | 1 |
| 12 | Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB <i>Value in Health</i> , 2022 , 25, 525-533 | 3.3 | 1 |
| 11 | Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study <i>Journal of Clinical Oncology</i> , 2020 , 38, e22102-e22102 | 2.2 | 1 |

| 10 | Development of an Instrument to Assess the Perceived Effectiveness of Academic Detailing. Journal of Continuing Education in the Health Professions, 2020 , 40, 235-241 | 2.1 | 1 |
|----|---|-----|---|
| 9 | Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality. <i>European Journal of Health Economics</i> , 2021 , 22, 17-33 | 3.6 | 1 |
| 8 | United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument. <i>Medical Decision Making</i> , 2021 , 41, 485-501 | 2.5 | O |
| 7 | Hospitalizations for opioid-related overdose and timing of concurrent opioid and benzodiazepine use: A nested case-control study. <i>Pharmacotherapy</i> , 2021 , 41, 722-732 | 5.8 | O |
| 6 | Coded cause of death and timing of COPD diagnosis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 41-7 | 2 | |
| 5 | Importation of prescription medications: experiences, opinions, and intended behaviors of U.S. community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004 , 44, 666-72 | 1.7 | |
| 4 | RESPONSE: Re: A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1786-1787 | 9.7 | |
| 3 | Secondary effects of an opioid-focused academic detailing program on non-opioid controlled substance prescribing in primary care. <i>Substance Abuse</i> , 2021 , 42, 962-967 | 3.8 | |
| 2 | Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PArTNER study <i>Journal of General Internal Medicine</i> , 2022 , 1 | 4 | |
| 1 | The Development of the EQ-5D-5L and its Value Sets 2022 , 1-12 | | |